Concepedia

Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer

Michael J. Morris, Chaitanya Divgi, Neeta Pandit‐Taskar, Maria Batraki, Nyasha Warren, Angelo Nacca, Peter Smith‐Jones, Lawrence H. Schwartz, William K. Kelly, Susan F. Slovin,

Clinical Cancer Research · 2005 · 114 citations · 19 references

DOIFull text

Open access

Abstract

J591 is well tolerated in repetitive dose-escalating administrations. The rate of serum clearance decreases with increasing antibody mass. ADCC activation is proportional to antibody mass. The optimal dose is 25 mg for radioimmunotherapy and 100 mg for immunotherapy. Phase II studies using J591 as a radioconjugate are under way.

References

19

Prostate-specific membrane antigen expression in normal and malignant human tissues.

Donald Silver, I Pellicer, W R Fair et al. · PubMed · 1997 · 1.5K citations

, , +11

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Sam S. Chang, Victor E. Reuter, W. D. W. Heston et al. · PubMed · 1999 · 814 citations

, , +11

Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support

Oliver W. Press, Janet F. Eary, Frederick R. Appelbaum et al. · New England Journal of Medicine · 1993 · 650 citations · Full text

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

George L. Wright, B. Mayer Grob, Cara Haley et al. · Urology · 1996 · 624 citations

, , +3

Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.

Ron Israeli, C. Thomas Powell, William R. Fair et al. · PubMed · 1993 · 531 citations

, , +17